Outcomes after SRS and ipilimumab plus nivolumab for melanoma brain metastases following prior immune checkpoint inhibitor or targeted therapy
Concurrent SRS with ipi/nivo provides durable intracranial control with low toxicity. Patients with prior ICI or targeted therapy represent a high-risk subgroup with poorer outcomes, supporting exploration of intensified or novel strategies.
Authors
- Melanie Berger (ORCID: https://orcid.org/0000-0002-6227-618X)
- Ahron Flowers (ORCID: https://orcid.org/0000-0002-5579-1351)
- Michelle Alonso‐Basanta (ORCID: https://orcid.org/0000-0001-9214-7656)
- Robert A. Lustig (ORCID: https://orcid.org/0000-0003-0633-3802)
- Ian Messing (ORCID: https://orcid.org/0000-0003-2950-9823)
- Harper Hubbeling (ORCID: https://orcid.org/0000-0003-4812-5235)
- Mohan Suyash
- Michael A. Kallan
- S. Nagda
- Alexander C. Huang (ORCID: https://orcid.org/0000-0002-0099-0492)
- Xingmei Wang (ORCID: https://orcid.org/0000-0002-0281-0336)
- John Y. K. Lee
- Ravi K. Amaravadi
- Jay F. Dorsey
- Goldie Kurtz
- Tara C. Mitchell
- Matthew D Riina
- Emily S Lebow
- Nduka M Amankulor
- Jonathan Baron
- Lauren Linkowski
- J Nicholas Lukens
- Christina Jackson
Institutions
- University of Pennsylvania (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1093/oncolo/oyag043
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00